Bernard L, Legout L, Zürcher-Pfund L, Stern R, Rohner P, Peter R, Assal M, Lew D, Hoffmeyer P, Uçkay I: Six weeks of antibiotic treatment is sufficient following surgery for septic arthroplasty. J Infect 2010, 61: 125-132. 10.1016/j.jinf.2010.05.005
Article
Google Scholar
Bliziotis IAF, Ntziora F, Lawrence KR, Falagas ME: Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials. Eur J Clin Microbiol Infect Dis 2007, 26: 849-856. 10.1007/s10096-007-0378-1
Article
Google Scholar
Boselli E, Breilh D, Rimmele T, Guillaume C, Xuereb F, Saux MC, Bouvet L, Chassard D, Allaouchiche B: Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med 2008, 36: 1500-1506. 10.1097/CCM.0b013e318170ba21
Article
Google Scholar
Brandt CM, Rouse MS, Tallan BM, Wilson WR, Steckelberg JM: Failure of time-kill synergy studies using subinhibitory antimicrobial concentrations to predict in vivo antagonism of cephalosporin-rifampin combinations against Staphylococcus aureus . Antimicrob Agents Chemother 1994, 38: 2191-2193. 10.1128/AAC.38.9.2191
Article
Google Scholar
Clinical and Laboratory Standards Institute CLSI: Performance Standards for Antimicrobial Susceptibility Testing; 17th Informational Supplement. Wayne, PA; 2008.
Google Scholar
Czekaj J, Dinh A, Moldovan A, Vaudaux P, Gras G, Hoffmeyer P, Lew D, Bernard L, Uçkay I: Efficacy of a combined oral clindamycin-rifampicin regimen for therapy of staphylococcal osteoarticular infections. Scand J Infect Dis 2011, 43: 962-967. 10.3109/00365548.2011.608082
Article
Google Scholar
Drusano GL: Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2004, 2: 289-300. 10.1038/nrmicro862
Article
Google Scholar
Hackbarth CJ, Chambers HF, Sande MA: Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus . Antimicrob Agents Chemother 1986, 29: 611-613. 10.1128/AAC.29.4.611
Article
Google Scholar
Howden BP, Richards MJ: The efficacy of continuous infusion flucloxacillin in home therapy for serious staphylococcal infections and cellulitis. J Antimicrob Chemother 2001, 48: 311-314. 10.1093/jac/48.2.311
Article
Google Scholar
Jugun K, Vaudaux P, Garbino J, Pagani L, Hoffmeyer P, Lew D, Uçkay I: The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections. Int Orthop 2013, 37: 1375-1380. 10.1007/s00264-013-1856-y
Article
Google Scholar
Landersdorfer CB, Kirkpatrick CM, Kinzig-Schippers M, Bulitta JB, Holzgrabe U, Drusano GL, Sorgel F: Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob Agents Chemother 2007, 51: 3290-3297. 10.1128/AAC.01410-06
Article
Google Scholar
Le T, Bayer AS: Combination antibiotic therapy for infective endocarditis. Clin Infect Dis 2003, 36: 615-621. 10.1086/367661
Article
Google Scholar
Leder K, Turnidge JD, Korman TM, Grayson ML: The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother 1999, 43: 113-118. 10.1093/jac/43.1.113
Article
Google Scholar
Massanari RM, Donta ST: The efficacy of rifampin as adjunctive therapy in selected cases of staphylococcal endocarditis. Chest 1978, 73: 371-375. 10.1378/chest.73.3.371
Article
Google Scholar
National Committee for Clinical Laboratory Standards NCCLS: Methodology for the Serum Bactericidal Test. Approved Standard M21-A. Wayne, PA; 1999.
Google Scholar
Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG: Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008, 168: 805-819. 10.1001/archinte.168.8.805
Article
Google Scholar
Swanberg L, Tuazon CU: Rifampin in the treatment of serious staphylococcal infections. Am J Med Sci 1984, 287: 49-54. 10.1097/00000441-198405000-00018
Article
Google Scholar
Trampuz A, Zimmerli W: Diagnosis and treatment of infections associated with fracture-fixation devices. Injury 2006, 37: 59-66.
Article
Google Scholar
Uçkay I, Pittet D, Vaudaux P, Sax H, Lew D, Waldvogel F: Foreign body infections due to Staphylococcus epidermidis . Ann Med 2009, 41: 109-119. 10.1080/07853890802337045
Article
Google Scholar
Van der Auwera P, Klastersky J: In vitro study of the combination of rifampin with oxacillin against Staphylococcus aureus . Rev Infect Dis 1983, 5: 509-514. 10.1093/clinids/5.Supplement_3.S509
Article
Google Scholar
Van der Auwera P, Meunier-Carpentier F, Klastersky J: Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections. Rev Infect Dis 1983, 5: 515-522.
Article
Google Scholar
Van der Auwera P, Klastersky J, Thys JP, Meunier-Carpentier F, Legrand JC: Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 1985, 28: 467-472. 10.1128/AAC.28.4.467
Article
Google Scholar
Widmer AF, Gaechter A, Ochsner PE, Zimmerli W: Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis 1992, 14: 1251-1253. 10.1093/clinids/14.6.1251
Article
Google Scholar
Zak O, Scheld WM, Sande MA: Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits. Rev Infect Dis 1983, 5: 481-490. 10.1093/clinids/5.Supplement_3.S481
Article
Google Scholar
Zavasky DM, Sande MA: Reconsideration of rifampin: a unique drug for a unique infection. JAMA 1998, 279: 1575-1577. 10.1001/jama.279.19.1575
Article
Google Scholar
Zinner SH, Husson M, Klastersky J: Effect of mixing on rifampin bactericidal activity against staphylococci. Antimicrob Agents Chemother 1981, 20: 267-269. 10.1128/AAC.20.2.267
Article
Google Scholar
Zinner SH, Lagast H, Klastersky J: Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis 1981, 144: 365-371. 10.1093/infdis/144.4.365
Article
Google Scholar